课题基金 / 基金详情

Saving Sight Through Novel BioTech Innovations for Inherited Retinal Disease

Saving Sight Through Novel BioTech Innovations for Inherited Retinal Disease
通过针对遗传性视网膜疾病的新型生物技术创新来拯救视力
批准号:
nhmrc : 1195713
负责人:
金额:
$153.45万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Investigator Grants
财政年份:
2022
资助国家:
澳大利亚
项目状态:
未结题
起止时间:
2022-01-01 至 2026-12-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
遗传性视网膜疾病(IRD)是工作年龄成人失明的主要原因。我的工作重点是更多地了解IRD,包括基因与眼睛退行性变化之间的相关性。我正在开发新的结果测量方法来预测谁可能更快地失去视力,并用于临床试验。然后,我将在两个新的IRD治疗临床试验中使用这些知识-基因疗法和植入眼睛的电子设备。
英文摘要
Inherited retinal diseases (IRDs) are the leading cause of blindness in working-aged adults. My work focuses on learning more about IRDs, including the correlation between genes and the degenerative changes in the eye. I am developing new outcome measures to predict who might lose vision faster, and to use in clinical trials. I will then use this knowledge in two clinical trials for new IRD treatments - a gene therapy and an electronic device that is implanted into the eye.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金